Literature DB >> 25345868

Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome.

G Ponti1, E Castellsagué, C Ruini, A Percesepe, A Tomasi.   

Abstract

Founder mutations in specific populations are common in several Mendelian disorders. They are shared by apparently unrelated families that inherited them from a common ancestor that existed hundreds to thousands of years ago. They have been proven to impact in molecular diagnostics strategies in specific populations, where they can be assessed as the first screening step and, if positive, avoid further expensive gene scanning. In Lynch syndrome (LS), a dominantly inherited colorectal cancer disease, more than 50 founder pathogenic mutations have been described so far in the mismatch repair (MMR) genes (MLH1, MSH2, MSH6 and PMS2). We here provide a comprehensive summary of the founder mutations found in the MMR genes and an overview of their main characteristics. At a time when high-throughput strategies are being introduced in the molecular diagnostics of cancer, genetic testing for founder mutations can complement next generation sequencing (NGS) technologies to most efficiently identify MMR gene mutations in any given population. Additionally, special attention is paid to MMR founder mutations with interesting anthropological significance.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HNPCC; Lynch syndrome; MLH1; MMR; MSH2; MSH6; Muir-Torre syndrome; PMS2; founder mutation; genetic anticipation phenomenon

Mesh:

Substances:

Year:  2014        PMID: 25345868     DOI: 10.1111/cge.12529

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  22 in total

Review 1.  Recent advances in Lynch syndrome.

Authors:  Leah H Biller; Sapna Syngal; Matthew B Yurgelun
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

2.  Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Authors:  Giovanni Germano; Simona Lamba; Giuseppe Rospo; Ludovic Barault; Alessandro Magrì; Federica Maione; Mariangela Russo; Giovanni Crisafulli; Alice Bartolini; Giulia Lerda; Giulia Siravegna; Benedetta Mussolin; Roberta Frapolli; Monica Montone; Federica Morano; Filippo de Braud; Nabil Amirouchene-Angelozzi; Silvia Marsoni; Maurizio D'Incalci; Armando Orlandi; Enrico Giraudo; Andrea Sartore-Bianchi; Salvatore Siena; Filippo Pietrantonio; Federica Di Nicolantonio; Alberto Bardelli
Journal:  Nature       Date:  2017-11-29       Impact factor: 49.962

Review 3.  Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine.

Authors:  Laura Valle; Eduardo Vilar; Sean V Tavtigian; Elena M Stoffel
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

4.  Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now.

Authors:  Anthony Scott; Arathi Mohan; Sarah Austin; Erika Amini; Shelby Raupp; Brittany Pannecouk; Michael J Kelley; Goutham Narla; Nithya Ramnath
Journal:  JCO Oncol Pract       Date:  2022-03-08

Review 5.  Recent progress in Lynch syndrome and other familial colorectal cancer syndromes.

Authors:  Patrick M Boland; Matthew B Yurgelun; C Richard Boland
Journal:  CA Cancer J Clin       Date:  2018-02-27       Impact factor: 508.702

6.  A novel founder MSH2 deletion in Ethiopian Jews is mainly associated with early-onset colorectal cancer.

Authors:  I Kedar; L Walsh; G Reznick Levi; S Lieberman; A Abu Shtaya; S Naftaly Nathan; I Lagovsky; R Tomashov-Matar; M Goldenberg; L Basel-Salmon; L Katz; O Aleme; T Yablonski Peretz; A Hubert; D Rothstein; S Castellvi-Bel; T Walsh; M C King; C C Pritchard; Z Levi; E Half; I Laish; Y Goldberg
Journal:  Fam Cancer       Date:  2021-04-10       Impact factor: 2.375

Review 7.  Update on Lynch syndrome genomics.

Authors:  Päivi Peltomäki
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

Review 8.  Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.

Authors:  Aniello Cerrato; Francesco Morra; Angela Celetti
Journal:  J Exp Clin Cancer Res       Date:  2016-11-24

9.  A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America.

Authors:  Benedito Mauro Rossi; Edenir Inêz Palmero; Francisco López-Kostner; Carlos Sarroca; Carlos Alberto Vaccaro; Florencia Spirandelli; Patricia Ashton-Prolla; Yenni Rodriguez; Henrique de Campos Reis Galvão; Rui Manuel Reis; André Escremim de Paula; Luis Gustavo Capochin Romagnolo; Karin Alvarez; Adriana Della Valle; Florencia Neffa; Pablo German Kalfayan; Enrique Spirandelli; Sergio Chialina; Melva Gutiérrez Angulo; Maria Del Carmen Castro-Mujica; Julio Sanchez de Monte; Richard Quispe; Sabrina Daniela da Silva; Norma Teresa Rossi; Claudia Barletta-Carrillo; Susana Revollo; Ximena Taborga; L Lena Morillas; Hélène Tubeuf; Erika Maria Monteiro-Santos; Tamara Alejandra Piñero; Constantino Dominguez-Barrera; Patrik Wernhoff; Alexandra Martins; Eivind Hovig; Pål Møller; Mev Dominguez-Valentin
Journal:  BMC Cancer       Date:  2017-09-05       Impact factor: 4.430

Review 10.  Recent advances in Lynch syndrome.

Authors:  Xi Li; Guodong Liu; Wei Wu
Journal:  Exp Hematol Oncol       Date:  2021-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.